INTRODUCTION {#sec1-1}
============

Asians have a wider lower-third face than Caucasians, which generally is less acceptable to females. This can be secondary to the bony configuration or soft tissue enlargement (masseter muscle hypertrophy, parotid gland enlargement, etc.). Masseteric hypertrophy is a benign condition first described in 1880.\[[@ref1]\] Many medical (systemic muscle relaxants) and surgical (muscle resection and modelling ostectomy) treatment options have evolved for its management. Various side-effects of medications and unpredictable results/ complications of surgery have reduced the demand for treatment.\[[@ref2]\]

Moore and Wood used type-A botulinum toxin (T-ABT) injection for functional management of masseter hypertrophy. This eventually led Rijsdijk *et al.*, to its cosmetic use for muscle hypertrophy.\[[@ref1][@ref3]\] Gradually, botulinum toxin was used frequently due to its predictable results as compared to systemic medications and surgery. Most important limitation for botulinum toxin is its temporary effect for every condition. We report the extended effect of T-ABT single injection for asymmetric masseter hypertrophy in a male patient.

CASE REPORT {#sec1-2}
===========

A 35 -year -old Indian male presented to our oculofacial aesthetics clinic with a bulky appearing lower face since his adolescence. He was not having any other ocular and periocular complaint. He had not received botulinum toxin treatment previously for the same condition. There was no history of local trauma or surgery. There was no history of any mental stress or bruxism reported by family members. He had normal eating habits (no habitual tobacco/betel-nut, chewing-gum or hard food chewing). On facial inspection, the lower-third of face, specifically mandibular angle region appeared to be prominent on left side \[[Figure 1](#F1){ref-type="fig"}\]. On teeth clenching, bilateral masseter muscle became prominent which on palpation appeared as localised single longitudinal bulge, that is, type II hypertrophy according to the Xie\'s classification. No additional findings were detected on inspection or palpation. His oral and dental examinations were within normal limits. The jaw movements (forward, sideways, and mastication) were confirmed to be normal and the magnitude with dimensions of smile was recorded as clinical pictures.

![Before botulinum toxin injection, (A) (Front view, without clenching teeth) gross asymmetric lower face with prominence in masseteric region suggestive of masseter hypertrophy, (B) (Oblique view, with clenched teeth) left sided masseteric region showing prominent muscle with local single longitudinal bulge (Xie\'s type II)](IJPS-48-196-g001){#F1}

B-scan ultrasonography (USG) (8 M Hz) was performed for objective measurement of both masseter muscles and to rule out any occult or unsuspected local pathology (parotid enlargement). In unclenched state, right masseter muscle thickness was 13 mm while that of left was 14.9 mm (asymmetry --- 1.9 mm) \[[Figure 2](#F2){ref-type="fig"}\]. Intramuscular T-ABT was planned for both masseters after explaining the temporary effect and need for re-treatment to the patient. The "safe zone" for intramuscular injection was marked between the upper limit defined by a line joining the tragus and angle of mouth while anterior and posterior borders of masseter were highlighted in clenched state \[[Figure 3](#F3){ref-type="fig"}\]. This "safe zone" has no anatomically vital structures hence lesser chances for related complications. Freshly prepared T-ABT was injected into the thickest part of each muscle in a diamond shape, equally at five points. The dose was titrated according to the muscle thickness, that is, 15 and 25 international units (IU) into right and left muscle. The patient was kept under observation for 30 min after injection, to monitor for any adverse reactions.

![Ultrasound B-scan pictures with calliper markings, (A) At the most prominent part, the right masseter muscle is 13 mm in thickness while the left muscle is 14.9 mm thick, (B) The right and left masseter muscles are reduced to 10.1 mm and 10.5 mm, respectively, signifying the achievement of symmetry on both sides](IJPS-48-196-g002){#F2}

![Defining the "safe zone" marking for the masseter muscle. The superior border of muscle is marked by green line, the anterior border being palpated with middle finger of left hand while 29 gauge needle being used to inject the toxin at its most prominent region in a diamond shape (marks shown as dots)](IJPS-48-196-g003){#F3}

On follow-up, the ultrasound was repeated to detect the muscle thickness. At 6 months, USG showed a reduction of 2.9 mm and 4.4 mm in the right and left masseter muscles, respectively \[[Figure 2](#F2){ref-type="fig"}\]. There was a prominent effect on asymmetry too, as it reduced from 1.9 mm to 0.4 mm. There were no significant side-effects (abnormal mastication or paradoxical bulging) in early or late post-injection period. At 24 months of followup, the patient was satisfied with the maintained symmetrical facial appearance as the outcome \[[Figure 4](#F4){ref-type="fig"}\]. The USG at last follow-up shows asymmetry of 0.2 mm.

![24 months follow-up, (A) (Front view, without clenching teeth) lower face appears less broad secondary to reduced thickness of masseter muscle, (b) (Oblique view with clenched teeth) left sided view of masseteric region showing flatter masseter muscle without the bulge and less bulkier appearance of mandibular region](IJPS-48-196-g004){#F4}

DISCUSSION {#sec1-3}
==========

The dosage regimen and duration of effect of T-ABT for masseter hypertrophy has yet not been standardised.\[[@ref4]\] In 2005, Kim *et al.* recommended 100- 140 units of Dysport (Ipsen Ltd, Slough, United Kingdom) for 10- 16 mm thickness while Choe *et al.* suggested using \> 20 IU of Botox (Allergan, Inc., Irvine, California) for any thickness \>10 mm.\[[@ref1][@ref5]\] Recently, Xie *et al.* classified the masseter hypertrophy and tailored the dose of T-ABT for defining the number, dosage, effect, and complications of the drug.\[[@ref6]\] Overall, the literature suggests 20-50 IU of T-ABT/ muscle for treating the masseteric hypertrophy.\[[@ref6]\] Following T-ABT, most patients experience the reduction in muscle mass (atrophic effect) at 2-4 weeks with an average reduction being 31% of muscle thickness.\[[@ref4]\] However, the duration of toxin effect varies individually, hence not predictable.

The effect of T-ABT appears as reduction in the power of muscle contraction, muscle tone, and later-on reduced muscle volume which can be measured with the help of electromyography, USG, computed tomography, and three-dimensional scanning.\[[@ref7]\] The induction of this effect follows two stages --- "tension reduction" followed by "volume reduction" and the recovery also respects this evolution, that is, "tension recovery" followed by "volume recovery".\[[@ref4]\] The anatomical and cosmetic effect of toxin can be well-documented by ultrasound and patient\'s clinical pictures with the help of critical software based analysis, before and after treatment.\[[@ref1][@ref5][@ref7]\]

Anatomically, masseter muscle fibres lie in layered fashion, which are innervated by separate nerve bundles. This advocates its particular contraction characteristics and supports the wider distribution of toxin. The multiple injection points ensure homogenous drug distribution, lesser dose and lesser side-effects, which can theoretically prevent drug resistance. The aim of this treatment is "volume reduction" which is achieved later and stays longer even while the toxin effect is gone. This is in contrast to the desired "tension reduction" effect for dynamic facial muscle wrinkles which appears early and regresses early.\[[@ref4]\]

The mechanism of botulinum toxin is to induce "disuse atrophy" in a muscle which may or may not be having the "overuse hypertrophy". As the effect of toxin weans off in balanced muscles (masseter), a "balanced recovery" can be predicted achieving symmetry which is one of the desired outcomes. The symmetric appearance of the face was the more important criteria for our patient satisfaction which can be achieved and can have an extended effect even at 24 months of followup. This validates the longer and extended "volume reduction" result of botulinum toxin in masseter muscle hypertrophy.
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